Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Cancer Prev Res (Phila). 2022 Apr 1;15(4):255–264. doi: 10.1158/1940-6207.CAPR-21-0467

Table 3:

Hazard ratios for the association of predicted REE (Ikeda) with risk of incident, invasive breast cancer in postmenopausal women, overall and by breast cancer subtype

Quintiles


1 2 3 4 5 P-trend


Invasive breast cancer
 Cases (N) 1,887 1,865 1,896 1,870 1,858
 Age-adjusted HR (95% CI) 1.00 1.05 (0.99–1.12) 1.13 (1.06–1.20) 1.26 (1.18–1.35) 1.44 (1.35–1.54) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.11 (1.04–1.18) 1.23 (1.15–1.31) 1.43 (1.33–1.53) 1.69 (1.57–1.81) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.06 (0.99–1.14) 1.14 (1.06–1.23) 1.28 (1.17–1.39) 1.39 (1.23–1.57) <0.001
ER+/PR+ breast cancer
 Cases (N) 1,164 1,191 1,258 1,229 1,249
 Age-adjusted HR (95% CI) 1.00 1.12 (1.03–1.22) 1.27 (1.17–1.37) 1.42 (1.31–1.54) 1.70 (1.57–1.85) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.16 (1.07–1.47) 1.58 (1.46–1.72) 1.96 (1.46–1.72) 1.96 (1.80–2.14) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.11 (1.02–1.21) 1.25 (1.14–1.37) 1.40 (1.25–1.56) 1.58 (1.36–1.84) 0.017
ER+/PR− breast cancer
 Cases (N) 269 280 226 207 197
 Age-adjusted HR (95% CI) 1.00 1.15 (0.98–1.37) 0.99 (0.83–1.19) 1.04 (0.87–1.26) 1.17 (0.97–1.41) 0.376
 Multivariable-adjusted* HR (95% CI) 1.00 1.17 (0.99–1.39) 1.03 (0.86–1.23) 1.10 (0.91–1.33) 1.24 (1.02–1.52) 0.128
 Multivariable-adjusted** HR (95% CI) 1.00 1.17 (0.98–1.40) 1.03 (0.83–1.27) 1.11 (0.86–1.43) 1.24 (0.87–1.78) 0.557
ER−/PR− breast cancer
 Cases (N) 231 229 218 235 202
 Age-adjusted HR (95% CI) 1.00 1.05 (0.88–1.26) 1.05 (0.87–1.26) 1.28 (1.06–1.53) 1.24 (1.02–1.50) 0.004
 Multivariable-adjusted* HR (95% CI) 1.00 1.05 (0.88–1.27) 1.04 (0.86–1.26) 1.25 (1.04–1.52) 1.17 (0.95–1.44) 0.035
 Multivariable-adjusted** HR (95% CI) 1.00 1.01 (0.83–1.23) 0.97 (0.78–1.20) 1.11 (0.86–1.43) 0.95 (0.66–1.36) 0.746
Localised
 Cases (N) 1,434 1,423 1,452 1,378 1,355
 Age-adjusted HR (95% CI) 1.00 1.09 (1.01–1.17) 1.18 (1.10–1.27) 1.29 (1.20–1.39) 1.49 (1.38–1.85) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.12 (1.04–1.21) 1.26 (1.17–1.35) 1.42 (1.32–1.54) 1.69 (1.56–1.84) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.09 (1.01–1.18) 1.19 (1.10–1.30) 1.31 (1.18–1.46) 1.47 (1.28–1.70) <0.001
Advanced
 Cases (N) 394 407 404 441 435
 Age-adjusted HR (95% CI) 1.00 1.11 (0.96–1.27) 1.16 (1.01–1.33) 1.43 (1.25–1.64) 1.61 (1.40–1.87) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.12 (0.98–1.29) 1.19 (1.03–1.37) 1.48 (1.29–1.71) 1.68 (1.44–1.71) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.06 (0.91–1.22) 1.06 (0.90–1.25) 1.25 (1.03–1.50) 1.23 (0.95–1.59) 0.038
Low grade
 Cases (N) 528 500 499 468 434
 Age-adjusted HR (95% CI) 1.00 1.02 (0.90–1.16) 1.09 (0.96–1.23) 1.17 (1.03–1.32) 1.27 (1.11–1.44) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.06 (0.94–1.20) 1.17 (1.03–1.33) 1.32 (1.16–1.51) 1.52 (1.32–1.74) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.03 (0.90–1.17) 1.10 (0.95–1.28) 1.20 (1.01–1.43) 1.28 (1.00–1.64) 0.024
Intermediate grade
 Cases (N) 811 775 807 778 796
 Age-adjusted HR (95% CI) 1.00 1.04 (0.94–1.15) 1.16 (1.05–1.28) 1.28 (1.16–1.41) 1.53 (1.38–1.69) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.07 (0.97–1.19) 1.23 (1.11–1.36) 1.42 (1.28–1.57) 1.76 (1.58–1.95) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.04 (0.94–1.15) 1.16 (1.03–1.30) 1.29 (1.13–1.48) 1.49 (1.23–1.80) <0.001
High grade
 Cases (N) 375 415 398 440 448
 Age-adjusted HR (95% CI) 1.00 1.20 (1.04–1.38) 1.22 (1.06–1.40) 1.53 (1.33–1.76) 1.79 (1.56–2.06) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.21 (1.05–1.40) 1.24 (1.07–1.43) 1.57 (1.36–1.81) 1.81 (1.56–2.10) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.17 1.01–1.37) 1.16 (0.99–1.37) 1.43 (1.18–1.72) 1.54 (1.19–1.99) <0.001

Abbreviations: REE= resting energy expenditure, HR= hazard ratio; CI= confidence interval; ER = estrogen receptor, PR= progesterone receptor

*

Also adjusted for education, physical activity, smoking status, alcohol consumption, randomization group/study arm, unopposed estrogen therapy ever use, combined estrogen and progesterone therapy use ever, breastfed ever, age at menopause, oral contraceptive, healthy eating index 2015, age at menarche and age at first full‐term pregnancy, race and ethnicity

**

Also adjusted for BMI